Clinical Trial Update: A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma [Phase 2]

View source ↗

Summary

This update reports results from a Phase II trial of the PD-L1 inhibitor avelumab in patients with recurrent or progressive osteosarcoma; the study is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteosarcoma

Drugs mentioned

• Avelumab (avelumab)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Osteosarcoma | Phase 2 | Status: COMPLETED | Results posted: 2021-09-16